Bone marrow-derived mononuclear cells for ischemic stroke

This study aims to assess the safety of autologous bone marrow transplantation within 90 days of the onset of symptoms of ischemic stroke in the middle cerebral artery region. One study case demonstrated reduced cerebral edema and increased metabolism subsequent to improvement in speech and in the hemiparesis initially displayed.